Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Launched by NOVO NORDISK A/S · Feb 11, 2009
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • After the physician decision has been made to use biphasic insulin aspart 30 or insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before.Particular attention should be paid to the drug interactions that are listed within the product label
- Exclusion Criteria:
- • Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit
- • Subjects currently being treated with biphasic insulin aspart 30 or insulin detemir
- • Subjects who were previously enrolled in this study
- • Subjects with a hypersensitivity to biphasic insulin aspart 30 or insulin detemir or to any of the excipients
- • Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Skopje, , Macedonia, The Former Yugoslav Republic Of
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials